SRR1797285
— · cohortSC
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSC
- subtype
- cohortSC
- age_years
- 52
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- G2M_CHECKPOINT+0.460
- MYC_TARGETS_V1+0.410
- MITOTIC_SPINDLE+0.380
- PROTEIN_SECRETION+0.300
- DNA_REPAIR+0.270
- PEROXISOME+0.250
- SPERMATOGENESIS+0.250
- OXIDATIVE_PHOSPHORYLATION+0.240
- PANCREAS_BETA_CELLS+0.240
Top 10 suppressed
- ANGIOGENESIS-0.530
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.510
- IL6_JAK_STAT3_SIGNALING-0.500
- INFLAMMATORY_RESPONSE-0.460
- TNFA_SIGNALING_VIA_NFKB-0.450
- APICAL_SURFACE-0.440
- COAGULATION-0.430
- IL2_STAT5_SIGNALING-0.380
- NOTCH_SIGNALING-0.360
- MYOGENESIS-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1797245 | — | cohortSC | 0.943 |
| 2 | SRR1797279 | — | cohortSC | 0.937 |
| 3 | SRR1797277 | — | cohortSC | 0.926 |
| 4 | BS_HKZENFDA | medulloblastoma | — | 0.925 |
| 5 | BS_KYF0Q0E7 | medulloblastoma | — | 0.925 |
| 6 | SRR1797283 | — | cohortSC | 0.923 |
| 7 | SRR1797280 | — | cohortSC | 0.922 |
| 8 | BS_H4B5Y6S0 | medulloblastoma | — | 0.920 |
| 9 | BS_CHDGRYHJ | medulloblastoma | — | 0.917 |
| 10 | BS_Z7PKVY9J | medulloblastoma | — | 0.913 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.460 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.410 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.380 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.270 | Idelalisib | — uncovered |
| PEROXISOME | 0.250 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.250 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.240 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.240 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.210 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.170 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| FATTY_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |